<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">IMATINIB MESYLATE</span><br/>(i-ma'ti-nib)<br/><span class="topboxtradename">Gleevec<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">monoclonal antibody</span>; <span class="classification">tyrosine kinase inhibitor</span>; <span class="classification">immunosuppressant</span><br/><b>Prototype: </b>Gefitinib<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg capsule</p>
<h1><a name="action">Actions</a></h1>
<p>Tyrosine kinase inhibitor; inhibits the Bcr-Abl tyrosine kinase, an abnormal tyrosine kinase created by the Philadelphia chromosome
         abnormality in chronic myeloid leukemia (CLM). Tyrosine kinase is required for activation of a wide variety of intracellular
         activities vital to cell functioning; thus drug interferes with vital intracellular metabolic pathways.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits WBC cell proliferation and induces cell death in Bcr-Abl positive cells as well as in newly formed leukemic cells.
         Thus, it interferes with progression of chronic myeloid leukemia (CML).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of CML in blast crisis, or in chronic phase after failure of interferon-alpha therapy; unresectable and/or metastatic
         malignant gastrointestinal stromal tumors (GISTs).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Acute lymphocytic leukemia (ALL), soft tissue sarcoma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to imatinib or any of its components; viral infections, including herpes and chickenpox; intramuscular injections
         with concurrent thrombocytopenia; pregnancy (category D), lactation; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of hypersensitivity to other monoclonal antibodies; hepatic or renal impairment; bleeding, bone marrow suppression;
         cardiac disease; dental disease, dental work; older adults, females of childbearing age; fungal infections; GI bleeding; heart
         failure; hepatic disease; herpes infection, immunosuppression, infection; jaundice; neutropenia; peripheral edema, renal disease;
         thrombocytopenia, vaccination, varicella, viral infection; concurrent administration of drugs which are CYP3A4 inhibitors
         (i.e., ketoconazole, itraconazole, erythromycin, clarithromycin).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">CML Chronic Phase</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400800 mg q.d. with a meal and large glass of water<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;3 y</i>, 260 mg/m<sup>2</sup>/d in 1 or 2 divided dose(s) (max: 340 mg/m<sup>2</sup>/d)<br/><br/><span class="indicationtitle">CML Accelerated Phase or Blast Crisis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 600 mg q.d. with a meal and large glass of water<br/><br/><span class="indicationtitle">GISTs</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400600 mg q.d. times up to 24 mo<br/><br/><span class="impairmenttitle">Hepatic Impairment</span><br/>Reduce dose to 300 mg q.d. (chronic) or 400 mg q.d. (accelerated, blast crisis)<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with meal and large glass of water (at least 8 oz).</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Fluid retention, edema, fatigue,</span> weight gain, <span class="speceff-common">fever,</span> night sweats, weakness. <span class="typehead">CNS:</span>
<span class="speceff-life">CNS hemorrhage</span>, <span class="speceff-common">headache</span>. <span class="typehead"> GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea,</span>
<span class="speceff-life">GI hemorrhage</span>, dyspepsia, <span class="speceff-common">abdominal pain, constipation, anorexia,</span> increased AST, ALT, and bilirubin. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Hemorrhage,</span>
<span class="speceff-common">neutropenia, thrombocytopenia,</span> petechiae, epistaxis, <span class="speceff-life">pancytopenia</span> (rare), <span class="speceff-life">thrombocytopenia</span> (rare). <span class="typehead"> Metabolic:</span> Hypokalemia. <span class="typehead">Musculoskeletal:</span>
<span class="speceff-common">Muscle cramps, pain, arthralgia,</span> myalgia. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Cough, dyspnea,</span> pharyngitis, pneumonia. <span class="typehead">Skin:</span>
<span class="speceff-common">Rash,</span> pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Clarithromycin,</b>
<b>erythromycin,</b>
<b>ketoconazole,</b>
<b>itraconazole</b> may increase imatinib levels and toxicity; <b>carbamazepine,</b>
<b>dexamethasone,</b>
<b>phenobarbital,</b>
<b>phenytoin,</b>
<b>rifampin</b> may decrease imatinib levels; may increase levels of <span class="classification">benzodiazepines</span>, <span class="classification">dihydropyidine, calcium channel blockers</span> (e.g., <b>nifedipine</b>), <b>warfarin.</b>
<span class="typehead">Herbal:</span>
<b>St. John's wort</b> may decrease imatinib levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed, 98% reaches systemic circulation. <span class="typehead">Peak:</span> 24 h. <span class="typehead">Metabolism:</span> Metabolized primarily by CYP3A4 in liver. <span class="typehead">Elimination:</span> Primarily excreted in feces. <span class="typehead">Half-Life:</span> 18 h imatinib, 40 h active metabolite. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of fluid retention. Weigh daily and report rapid weight gain immediately.</li>
<li>Lab tests: CBC with platelet count and differential weekly times 1 mo, biweekly for the 2nd mo, periodically thereafter as
            clinically indicated; baseline and monthly AST, ALT, alkaline phosphatase, bilirubin; periodic serum creatinine and electrolytes.
         </li>
<li>Withhold drug and notify physician for any of the following: bilirubin &gt;3 times ULN, AST/ALT &gt;5 times ULN; treatment may be
            reinstituted when bilirubin 
         </li><li>Review concurrent medications. Consult physician about switching patients taking warfarin to low-molecular weight or standard
            heparin. Patients taking ketoconazole and other CYP3A4 inhibitors may experience increased adverse drug reactions.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not take any OTC drugs (e.g., acetaminophen, St. John's wort) without consulting physician.</li>
<li>Report any S&amp;S of bleeding immediately to physician (e.g., black tarry stool, bright red or coke colored urine, bleeding from
            gums).
         </li>
<li>Report immediately to physician any unexplained change in mental status.</li>
<li>Use effective means of contraception while taking this drug. Women of childbearing age should avoid becoming pregnant.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>